UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Antiviral therapy, 2017-01, Vol.22 (4), p.295-305

2017

Volltextzugriff (PDF)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

AIDS (London), 2015-01, Vol.29 (2), p.167-174

2015

Volltextzugriff (PDF)

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

Antiviral therapy, 2013-01, Vol.18 (7), p.905-913

2013

Volltextzugriff (PDF)

Dolutegravir plus Abacavir―Lamivudine for the Treatment of HIV-1 Infection

The New England journal of medicine, 2013-11, Vol.369 (19), p.1807-1818

2013

Volltextzugriff (PDF)

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

The New England journal of medicine, 2013-11, Vol.369 (19), p.1807-1818

2013

Volltextzugriff (PDF)

Georges-Paul Cuny L’HOMME QUI DÉCLARA LA GUERRE À LA MISÈRE: Albin Michel, 2014, 288 p., 19

Projet, 2015-03, Vol.N° 345 (2), p.92-93

Granier, Catherine

2015

Volltextzugriff (PDF)

Jean Viard, MARSEILLE, LE RÉVEIL VIOLENT D'UNE VILLE IMPOSSIBLE: L'Aube, 2014, 192 p., 13

Projet, 2014-10, Vol.N° 342 (5), p.93-94

Granier, Catherine

2014

Volltextzugriff (PDF)

Vincent de Gaulejac et Antoine Mercier, Manifeste pour sortir du mal-être au travail: Ddb éditions, 2012, 186 p., 15

Projet, 2013-11, Vol.N° 336-337 (5), p.186-186

Granier, Catherine

2013

Volltextzugriff (PDF)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

AIDS (London), 2015-11, Vol.29 (18), p.2459-2464

2015

Volltextzugriff (PDF)

Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Antiviral therapy, 2017, Vol.22 (5), p.459-460

2017

Volltextzugriff (PDF)

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

Journal of acquired immune deficiency syndromes (1999), 2015-12, Vol.70 (5), p.515-519

2015

Volltextzugriff (PDF)

Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir

HIV clinical trials, 2015-10, Vol.16 (5), p.170-177

2015

Volltextzugriff (PDF)

Vincent Cicchelli, PLURIEL ET COMMUN. Sociologie d’un monde cosmopolite: Presses de Sciences Po, 2016, 280p. 24

Projet, 2017, Vol.N° 356 (1), p.94-94

Granier, Catherine

2017

Volltextzugriff (PDF)

Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review

Pediatric anesthesia, 2019-11, Vol.29 (11), p.1094-1106

2019

Volltextzugriff (PDF)

Explosive growth in African combustion emissions from 2005 to 2030

Environmental research letters, 2014-03, Vol.9 (3), p.35003-10

2014

Volltextzugriff (PDF)

An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup

Pharmacology research & perspectives, 2023-02, Vol.11 (1), p.e01032-n/a

2023

Volltextzugriff (PDF)

Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments

Pediatric nephrology (Berlin, West), 2021-01, Vol.36 (1), p.83-91

2021

Volltextzugriff (PDF)

Historical (1850–2000) gridded anthropogenic and biomass burning emissions of reactive gases and aerosols: methodology and application

Atmospheric chemistry and physics, 2010-01, Vol.10 (15), p.7017-7039

2010

Volltextzugriff (PDF)

A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209)

Pharmaceutical research, 2017-09, Vol.34 (9), p.1840-1848

2017

Volltextzugriff (PDF)

Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103)

Nefrología, 2023-07, Vol.43 (4), p.458-466

2023

Volltextzugriff (PDF)

Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis

Pediatric nephrology (Berlin, West), 2021-07, Vol.36 (7), p.1765-1774

2021

Volltextzugriff (PDF)

Flaring emissions in Africa: Distribution, evolution and comparison with current inventories

Atmospheric environment (1994), 2019-02, Vol.199, p.423-434

2019

Volltextzugriff (PDF)

Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin

European journal of pharmaceutical sciences, 2018-03, Vol.114, p.46-54

2018

Volltextzugriff (PDF)

Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study

JAMA pediatrics, 2015-03, Vol.169 (3), p.230

2015

Volltextzugriff (PDF)

Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study

BMJ (Online), 2017-08, Vol.358, p.j3448

2017

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(121)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

Dolutegravir plus Abacavir―Lamivudine for the Treatment of HIV-1 Infection

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Georges-Paul Cuny L’HOMME QUI DÉCLARA LA GUERRE À LA MISÈRE: Albin Michel, 2014, 288 p., 19

Jean Viard, MARSEILLE, LE RÉVEIL VIOLENT D'UNE VILLE IMPOSSIBLE: L'Aube, 2014, 192 p., 13

Vincent de Gaulejac et Antoine Mercier, Manifeste pour sortir du mal-être au travail: Ddb éditions, 2012, 186 p., 15

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir

Vincent Cicchelli, PLURIEL ET COMMUN. Sociologie d’un monde cosmopolite: Presses de Sciences Po, 2016, 280p. 24

Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review

Explosive growth in African combustion emissions from 2005 to 2030

An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup

Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments

Historical (1850–2000) gridded anthropogenic and biomass burning emissions of reactive gases and aerosols: methodology and application

A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209)

Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103)

Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis

Flaring emissions in Africa: Distribution, evolution and comparison with current inventories

Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin

Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study

Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study

Suchergebnisse filtern